Artesunate-mefloquine
Phase 3Small molecule
NovartisArtesunate-mefloquine is one of 30 small molecule programs targeting Schistosomiasis. It is currently in Phase 3.
2
Indications
9
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
479 competitors in Malaria
#DrugCompanyPhaseTrials
1Artesunate-mefloquine
NovartisPhase 3
Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
Hydroxychloroquine Sulfate
NovartisPreclinical
Iron
WWatson Pharmaceuticals
Preclinical
IV LBH589
NovartisPreclinical
Mefloquine Plus Artesunate
Medicines for Malaria VenturePreclinical
IV Ceftriaxone
RRESnTEC, Institute of Research
Preclinical
RTS,S/AS01E
GSKPreclinical
Piperaquine
UUniversity of Oxford
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Malaria5 trials
Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria
Completed·—·Phase 2·NCT00243737·70 enrolled
Show 2 more trials
Malaria Elimination Pilot Study in Military Forces in Cambodia
Unknown status·—·Phase 4·NCT02653898·1,050 enrolled
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
Completed·—·Phase 3·NCT02974348·300 enrolled
ART1 trial
Schistosomiasis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Artesunate-mefloquine. EMBL-EBI & Wellcome Sanger Institute.
- [4]